Developer docs
API playgroundTry for free, no card

Search company profiles

Genoa Ventures

Full company profile

uuid00009t4

Namestring
Genoa Ventures
Legal namestring
Genoa Ventures
Websiteurl
genoavc.com
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, life sciences investing, early-stage funding, bioconvergence investing, portfolio investment management
Industry3 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAAAC
Late-Stage Venture Capital (Series C+)
NAICS code3 codes
  • Portfolio Management and Investment Advice523940
  • All Other Financial Investment Activities52399
  • Funds, Trusts, and Other Financial Vehicles525
SIC code2 codes
  • Investment Advice6282
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Venture Capital
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Fund Management
TypeManaged Services
Description

Genoa Ventures generates returns through management fees on funds under management and carried interest (performance fees) on successful portfolio exits. The firm manages over $150 million in assets across multiple funds, with returns realized through portfolio company exits via acquisitions and IPOs.

genoavc.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Genoa Ventures is a venture capital firm that deploys capital into early-stage life sciences companies at the convergence of biology and technology. The firm invests primarily at the seed and Series A stages, typically leading or co-leading rounds, and provides hands-on support including deal diligence and strategic guidance to portfolio companies. The firm manages over $150 million in assets across multiple funds and focuses on research tools, diagnostics, agriculture, animal health, bio-manufacturing, biodefense, industrial biology, synthetic biology, and genetic engineering.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Five FDA clearances across portfolio companies in 2025
+2 more records
Product overview1 text field

Genoa Ventures is a venture capital firm offering a single unified investment service rather than a platform-plus-modules architecture. The firm deploys capital and expertise to science-driven companies working at the intersection of biology and technology, with a focus on early-stage investments (typically seed or Series A). The firm manages over $150 million across three funds and invests across areas including research tools, diagnostics, agriculture, animal health, bio manufacturing, biodefense, industrial bio, synthetic biology, and genetic engineering. As a VC firm, Genoa does not offer discrete software products or modules but rather provides investment capital, strategic guidance, and operational support to portfolio companies.

Product and service1 record
1Genoa Ventures Investment Services
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Hawkwood Bio is the world's premier consultancy supporting industrial and food biotech companies with engineering, manufacturing, strategy, business development and fundraising services. Hawkwood founders Tony Day and Richard Kenny serve as Venture Partners at Genoa. The broader Hawkwood team actively sources and diligence investment opportunities in Industrial Bio and AgriFood, and provides deep industry expertise to Genoa portfolio companies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

General Inception is pioneering company creation as the first Igniter company, bringing a new way to partner with scientific inventors to ignite innovation and nurture transformational companies. As a Member Venture Capital company in General Inception, Genoa enjoys early access to new companies founded by General Inception. Partner Vikram Chaudhery is a Founder of General Inception, creating additional synergies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Early-stage venture firm investing at the intersection of science and technology, including life sciences, deep tech, and frontier computing. Comparable in stage, sector focus, and founder-friendly operating style.

TypeDirect peer
Description

Venture fund investing in early-stage life sciences, biotech, and healthcare companies. Direct competitor for seed and Series A life sciences deals with similar scientific thesis-driven approach.

TypeBroad incumbent
Description

One of the largest early-stage life sciences and technology venture firms, with a much broader portfolio and larger fund sizes. Competes for similar seed/Series A deals in biotech and genomics.

TypeDirect peer
Description

Early-stage life sciences venture firm that builds and invests in biotech startups. Directly comparable stage and sector focus, with a similar hands-on company-creation model.

TypeDirect peer
Description

Early-stage venture capital firm focused on life sciences, including biotech, pharmaceuticals, and medical devices. Comparable fund size and seed/Series A focus in life sciences.

TypeDirect peer
Description

Early-stage venture firm investing at the intersection of technology and biology, with a focus on synthetic biology and biotech. Very comparable in thesis, stage, and target founders.

TypeDirect peer
Description

Early-stage venture firm backing breakthrough scientific discoveries in life sciences, energy, and computing. Comparable seed/Series A focus on deep science and category-defining companies.

TypeBroad incumbent
Description

Large multi-stage venture firm with a dedicated bio/health fund investing across life sciences. Competes for similar deals but with substantially larger fund size and broader portfolio.

TypeBroad incumbent
Description

Early-stage venture firm investing across technology and science, with significant life sciences exposure. Comparable in stage and founder-friendly approach, though much larger and more diversified.

TypeDirect peer
Description

Healthcare-focused venture firm investing across biotech, medical devices, and diagnostics at early stages. Directly comparable in life sciences focus and early-stage deal activity.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment41 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genoa Ventures

Venture Capitalgenoavc.com

Genoa Ventures firmographics

Firmographics
Name
Genoa Ventures
Legal name
Genoa Ventures
Website
https://genoavc.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Genoa Ventures industry classification

Industry
Product category
Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), All Other Financial Investment Activities (52399), Funds, Trusts, and Other Financial Vehicles (525)
SIC
Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAAAC
Late-Stage Venture Capital (Series C+)

Keywords

  • Venture capital investing
  • Life sciences investing
  • Early-stage funding
  • Bioconvergence investing
  • Portfolio investment management

Where Genoa Ventures is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Genoa Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

Revenue model

  1. Venture Capital Fund Management: Genoa Ventures generates returns through management fees on funds under management and carried interest (performance fees) on successful portfolio exits. The firm manages over $150 million in assets across multiple funds, with returns realized through portfolio company exits via acquisitions and IPOs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Genoa Ventures product offering

Product offering

Core offering

Genoa Ventures is a venture capital firm that deploys capital into early-stage life sciences companies at the convergence of biology and technology. The firm invests primarily at the seed and Series A stages, typically leading or co-leading rounds, and provides hands-on support including deal diligence and strategic guidance to portfolio companies. The firm manages over $150 million in assets across multiple funds and focuses on research tools, diagnostics, agriculture, animal health, bio-manufacturing, biodefense, industrial biology, synthetic biology, and genetic engineering.

Product overview

Genoa Ventures is a venture capital firm offering a single unified investment service rather than a platform-plus-modules architecture. The firm deploys capital and expertise to science-driven companies working at the intersection of biology and technology, with a focus on early-stage investments (typically seed or Series A). The firm manages over $150 million across three funds and invests across areas including research tools, diagnostics, agriculture, animal health, bio manufacturing, biodefense, industrial bio, synthetic biology, and genetic engineering. As a VC firm, Genoa does not offer discrete software products or modules but rather provides investment capital, strategic guidance, and operational support to portfolio companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Genoa Ventures Investment Services

Quantifiable outcome

  • Five FDA clearances across portfolio companies in 2025
  • +2 more outcomes

Companies that use Genoa Ventures

Customer profile

Named customers9 records

Segments2 records

Ideal customer profiles2 records

Genoa Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Genoa Ventures partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Hawkwood Biotech PartnerscoreStrategic or Co-development PartnerHawkwood Bio is the world's premier consultancy supporting industrial and food biotech companies with engineering, manufacturing, strategy, business development and fundraising services. Hawkwood founders Tony Day and Richard Kenny serve as Venture Partners at Genoa. The broader Hawkwood team actively sources and diligence investment opportunities in Industrial Bio and AgriFood, and provides deep industry expertise to Genoa portfolio companies.
  • General InceptioncoreStrategic or Co-development PartnerGeneral Inception is pioneering company creation as the first Igniter company, bringing a new way to partner with scientific inventors to ignite innovation and nurture transformational companies. As a Member Venture Capital company in General Inception, Genoa enjoys early access to new companies founded by General Inception. Partner Vikram Chaudhery is a Founder of General Inception, creating additional synergies.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Genoa Ventures competitors and assessment

Company assessment

Direct peers

  • Lux Capital: Early-stage venture firm investing at the intersection of science and technology, including life sciences, deep tech, and frontier computing. Comparable in stage, sector focus, and founder-friendly operating style.
  • Section 32: Venture fund investing in early-stage life sciences, biotech, and healthcare companies. Direct competitor for seed and Series A life sciences deals with similar scientific thesis-driven approach.
  • Atlas Venture: Early-stage life sciences venture firm that builds and invests in biotech startups. Directly comparable stage and sector focus, with a similar hands-on company-creation model.
  • 5AM Ventures: Early-stage venture capital firm focused on life sciences, including biotech, pharmaceuticals, and medical devices. Comparable fund size and seed/Series A focus in life sciences.
  • Civilization Ventures: Early-stage venture firm investing at the intersection of technology and biology, with a focus on synthetic biology and biotech. Very comparable in thesis, stage, and target founders.
  • Prime Movers Lab: Early-stage venture firm backing breakthrough scientific discoveries in life sciences, energy, and computing. Comparable seed/Series A focus on deep science and category-defining companies.
  • Versant Ventures: Healthcare-focused venture firm investing across biotech, medical devices, and diagnostics at early stages. Directly comparable in life sciences focus and early-stage deal activity.

Broad incumbents

  • ARCH Venture Partners: One of the largest early-stage life sciences and technology venture firms, with a much broader portfolio and larger fund sizes. Competes for similar seed/Series A deals in biotech and genomics.
  • Andreessen Horowitz (Bio/Health Fund): Large multi-stage venture firm with a dedicated bio/health fund investing across life sciences. Competes for similar deals but with substantially larger fund size and broader portfolio.
  • Khosla Ventures: Early-stage venture firm investing across technology and science, with significant life sciences exposure. Comparable in stage and founder-friendly approach, though much larger and more diversified.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Genoa Ventures social profiles

Digital presence

Genoa Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genoa Ventures leadership team

Management profile

Number of profiles

Profiles11 records

Genoa Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genoa Ventures M&A and investment

M&A and investment

M&A

Investments41 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genoa Ventures

What does Genoa Ventures do?

Genoa Ventures is a venture capital firm that deploys capital into early-stage life sciences companies at the convergence of biology and technology. The firm invests primarily at the seed and Series A stages, typically leading or co-leading rounds, and provides hands-on support including deal diligence and strategic guidance to portfolio companies. The firm manages over $150 million in assets across multiple funds and focuses on research tools, diagnostics, agriculture, animal health, bio-manufacturing, biodefense, industrial biology, synthetic biology, and genetic engineering.

Is Genoa Ventures a public or private company?

Genoa Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Genoa Ventures founded?

Genoa Ventures was founded in 2018. It employs 11 to 50 people.

Where is Genoa Ventures based?

Genoa Ventures is headquartered in San Francisco, United States, in the North America region.

How does Genoa Ventures make money?

One revenue line is on record: venture Capital Fund Management.

Who are Genoa Ventures's main competitors?

Direct peers on record are Lux Capital, Section 32, Atlas Venture, 5AM Ventures, Civilization Ventures, Prime Movers Lab and Versant Ventures. Broad incumbents are ARCH Venture Partners, Andreessen Horowitz (Bio/Health Fund) and Khosla Ventures.

Does Genoa Ventures have an API?

No public API is recorded for Genoa Ventures.

What industry is Genoa Ventures in?

Genoa Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizHydRegen Raises $8M Series A Led by Genoa Ventures to Expand Industrial Biocatalysis TechnologyHydRegen raised $8 million in a Series A led by Genoa Ventures to expand its biocatalysis technology. The funding will support adoption in agrochemicals, materials, and bulk chemical production, with claims of up to 40% cost reduction and lower emissions. The company plans to use the capital to expand customer adoption and develop additional industrial applications.HIT ConsultantEpitel Closes $26M to Commercialize REMI Remote EEG PlatformEpitel, Inc. closed a $26M Series B funding round co-led by Catalyst Health Ventures and Genoa Ventures to expand its REMI Remote EEG Monitoring System. The funding aims to address the access gap in EEG diagnostic capacity, particularly for the 9.2 million Americans experiencing seizures annually, of whom 40% lack basic EEG access. Epitel's REMI platform allows for continuous brain activity monitoring at home with AI-assisted event detection, improving diagnostic efficiency for neurologists.Medical BuyerEpitel raises USD 26M in Series B roundEpitel, Inc. announced the closing of a $26 million Series B financing round co-led by Catalyst Health Ventures and Genoa Ventures, with participation from new and existing investors. The funding will support market expansion of the company's REMI Remote EEG Monitoring System, which provides wireless, wearable brain monitoring with AI-driven seizure detection for extended periods outside hospital settings. With this capital, Epitel plans to expand its commercial field team to increase access to neurological care, particularly for the estimated 40 percent of Americans who lack access to EEG testing.Venture Capital Access OnlineEpitel Secures $26 Million Series B to Expand Remote Wireless EEG MonitoringEpitel closed a $26 million Series B co-led by Catalyst Health Ventures and Genoa Ventures to expand its REMI wireless EEG monitoring system. The funding will support commercial expansion, with the system cleared for patients as young as one year old. Epitel aims to make EEG accessible to millions of Americans with seizures.The Next WebOnly 27% of US hospitals can run an EEG. Epitel raised $26m.Epitel raised $26M in a Series B round to expand its wireless EEG system, which records up to 30 days. The company cites a 2023 study showing only 27% of US hospitals have EEG capacity, and 40% of patients lack access. The device is reimbursable under existing billing codes.FinSMEsEpitel Raises $26M in Series B FundingEpitel, a Salt Lake City-based AI-driven wireless brain health platform, raised $26M in Series B financing co-led by Catalyst Health Ventures and Genoa Ventures. The company will use the funds to expand commercial infrastructure, scaling sales, marketing, and customer experience teams, and accelerate ambulatory market access growth.BloombergBloomberg Businessweek Daily: Investing in Life SciencesBlackstone Life Sciences closed its latest life-sciences fund with $6.3 billion in commitments in late March, marking its largest haul for backing clinical trials of medicines and technologies. The firm, which manages approximately $17 billion in assets, typically invests in late-stage medicines invented by biotech and pharmaceutical companies in exchange for royalties on future sales, having invested up to $750 million in Moderna's flu vaccine development in 2024. Dr. Jenny Rooke, Founder and Managing Director of Genoa Ventures, joined the podcast to discuss the intersection of technology and health.InsideprecisionmedicineJPM 2026: Genoa Ventures’ Jenny Rooke on Next-Gen Clinical Assessment ToolsJenny Rooke, founder of Genoa Ventures, discussed at the 2026 J.P. Morgan Healthcare Conference her investment thesis backing deeply technical founders building infrastructure for biology and precision medicine. The venture capital firm highlights portfolio companies like InterVenn, which uses glycoproteomics for cancer diagnostics, and Aqtual, which analyzes circulating DNA fragment patterns to guide chronic disease therapy selection. Genoa Ventures' core thesis argues that multimodal biological data integration outperforms single-answer approaches in improving diagnosis, treatment, and monitoring.Rho8 Active VCs for Your Health Diagnostics StartupRho published a curated guide identifying eight venture capital firms active in the health diagnostics sector, including Genoa Ventures, SmartGateVC, and Catalyst Health Ventures. The article details each firm's investment stage preferences, geographic focus, and notable portfolio companies to assist founders in securing funding. It concludes by promoting Rho's integrated financial platform for managing capital post-funding.AxiosGenoa Ventures' Jenny Rooke explains life sciences investing strategyGenoa Ventures, led by founder and managing director Jenny Rooke, is positioning itself as a niche investor in life sciences technology during a period of sector-wide uncertainty. The article notes that despite challenges facing the drug development sector—including pharma tariffs, Most Favored Nation threats, and NIH grant pullbacks—Genoa's portfolio companies may benefit from certain tailwinds in the current environment. The article appears to be an Axios Pro exclusive preview or interview segment that is truncated before full details are provided.